Indications
Urinary tract infection
Aztreonam is indicated in the treatment of the following infections caused by susceptible aerobic Gram-negative micro-organisms
Urinary tract infections: Pyelonephritis, cystitis (initial and recurrent) and asymptomatic bacteriuria (including those due to pathogens resistant ... Read more
Aztreonam is indicated in the treatment of the following infections caused by susceptible aerobic Gram-negative micro-organisms
Urinary tract infections: Pyelonephritis, cystitis (initial and recurrent) and asymptomatic bacteriuria (including those due to pathogens resistant to the aminoglycosides, cephalosporins or penicillins).
Gonorrhea: Acute uncomplicated urogenital or anorectal infections.
Lower respiratory tract infections: Including pneumonia, bronchitis and lung infections in patients with cystic fibrosis.
Skin and soft tissue infections: Postoperative wounds, ulcers and burns.
Meningitis: Caused by Haemophilusinfluenzae or Neisseria meningitidis.
Gynecological infections: Pelvic Inflammatory Disease (PID), endometritis and pelvic cellulitis.
Intra-abdominal infections: Peritonitis.
Bacteremia/ septicemia: Septicemia caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa,Proteus mirabilis, Serratia marcescens and Enterobacter species.
Bone and joint infections: Osteomyelitis,septic arthritis.
Aztreonam is also indicated for adjunctive therapy to surgery in the management of infections caused by susceptible organisms. Patients with serious Pseudomonas infections may benefit from concurrent use of Aztreonam and an aminoglycoside because of their synergistic action.
Dosage And Administration
Adults: The usual dose of Aztreonam is 3 to 4 gm daily (maximum recommended dose is 8 gm daily). The dosage and route of administration should be determined by the susceptibility of the causative organisms, severity of infection and the condition of the patient. In case of Pseudomonas aeruginosa infections, 2 gm every 6 or 8 hours is recommended.
Children: The usual dosage for patients older than one week is 30 mg/kg/dose every 6 or 8 hours. For severe infections in patients 2 years of age or older, 50 mg/kg/dose every 6 or 8 hours is recommended.Dosage information is not yet available for new-born less than 1 week old.
Dosage Guideline for adult:
Urinary tract infections: 500 mg or 1 gm; 8 or 12 hourly
Moderately severe systemic infections: 1 g or 2 gm; 8 or 12 hourly
Severe systemic or life-threatening infections: 2 gm; 6 or 8 hourly
Maximum recommended dose is 8 gm/ day.
Dosage Guideline or pediatric:
Mild to moderate infections: 30 mg/kg; 8 hourly
Moderate to severe infections (2 years or older): 50 mg/kg; 6 or 8 hourly
Maximum recommended dose is 120 mg/ kg/ day.
Side Effects
Local reactions such as phlebitis/thrombophlebitis following IV administration and discomfort/swelling at the injection site following IM administration may occur. Systemic reactions like diarrhea, nausea and/or vomiting, and rash may occur. Other side effects include anaphylaxis, angioedema, bronchospasm, pancytopenia, neutropenia, thrombocytopenia, anemia, eosinophilia, leukocytosis, thrombocytosis, abdominal cramps, dermatitis, urticaria, pruritus, hypotension, flushing, seizure, weakness, headache, fever, malaise may occur.
Precautions And Warnings
In patients with impaired hepatic or renal function, appropriate monitoring is recommended during therapy.
Pregnancy And Lactation
Pregnancy Category B. Aztreonam crosses the placenta and enters the fetal circulation. So it should be used during pregnancy only if the potential benefit justifies the potential risk.
Aztreonam is excreted in breast milk in concentrations that are less than 1% of concentrations determined in simultaneously obtained maternal serum. Temporary discontinuation of nursing is recommended.